|
|
|
| Effects of the insulin pump and basal insulin therapy at meal for pregnant women with gestational diabetes mellitus on their neonatal prognosis |
| 1.Baoji Hightech Hospital, Baoji, Shanxi Province, 721000；2.Joint Logistic Support Force 987 Hospital, Baoji |
|
|
|
|
Abstract To analyze the effects of the insulin pump and basal insulin therapy at meal for pregnant women with gestational diabetes mellitus (GDM) on their neonatal prognosis. Methods: 147 pregnant women with GDM who were diagnosed and treated in the hospital were selected from May 2020 to December 2022, including 72 women who were treated with individualized insulin pump in group A and 75 patients who were treated with individualized basal insulin therapy at meal in group B. The gestational weeks at delivery, the proportions of the blood glucose reaching target during pregnancy after treatment and the requiring cesarean section of the women were compared between the two groups. The first minute Apgar score and the rates of the perinatal adverse complications, such as premature infants, macrosomia, fetal acute distress and neonatal hypoglycemiam, of the neonates were compared between the two groups. The obese situation of the infants at 3 and 12 months after born were followed and were compared between the two groups. Results: There were no significant diffrences in the gestational weeks at delivery, the proportions of the normal blood glucose level after treatment during pregnancy and the cesarean section needed, and the neonatal 1 min Apgar score of the women between the two groups (P>0.05). The incidence of the neonatal adverse perinatal complications (2.8%) of the women in group A was significantly lower than that (12.0%) of the women in group B. The incidence of the infant obesity (4.2%) in group A was significantly lower than that in group B (14.7%) in the 12th month after birth (all P<0.05). Conclusion: The insulin pump therapy for the pregnant women with GDM has the same effectiveness as the basal insulin therapy at meal in controlling their blood glucose level during pregnancy, and which is superior to the basal insulin therapy at meal in the reducing neonatal adverse perinatal complications and the infant obesity in the 12th month after birth.
|
|
|
|
|
|
|
|
|
